{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:44:47Z","timestamp":1790963087992,"version":"4.1.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2006,4,1]],"date-time":"2006-04-01T00:00:00Z","timestamp":1143849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2006,4]]},"DOI":"10.1016\/j.ygyno.2005.09.041","type":"journal-article","created":{"date-parts":[[2005,11,4]],"date-time":"2005-11-04T07:09:57Z","timestamp":1131088197000},"page":"126-131","source":"Crossref","is-referenced-by-count":86,"title":["Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers"],"prefix":"10.1016","volume":"101","author":[{"given":"Robert L.","family":"Coleman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell R.","family":"Broaddus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane C.","family":"Bodurka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith K.","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas W.","family":"Burke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"Kavanagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles F.","family":"Levenback","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Gershenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2005.09.041_bib1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/canjclin.55.1.10","article-title":"Cancer statistics, 2005","volume":"55","author":"Jemal","year":"2005","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2005.09.041_bib2","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","article-title":"Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome","volume":"344","author":"Druker","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2005.09.041_bib3","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat. Med."},{"key":"10.1016\/j.ygyno.2005.09.041_bib4","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s00268-004-7682-z","article-title":"Treatment of gastrointestinal stromal tumors with imatinib mesylate: a major breakthrough in the understanding of tumor-specific molecular characteristics","volume":"29","author":"de Mestier","year":"2005","journal-title":"World J. Surg."},{"key":"10.1016\/j.ygyno.2005.09.041_bib5","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1158\/1078-0432.CCR-1151-3","article-title":"Targeting the platelet-derived growth factor receptor in antivascular therapy for human ovarian carcinoma","volume":"10","author":"Apte","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2005.09.041_bib6","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1182\/blood-2004-10-3967","article-title":"Macrophage colony stimulating factor receptor, c-fms, is a novel target of imatinib","volume":"105","author":"Dewar","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ygyno.2005.09.041_bib7","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1158\/1078-0432.CCR-0754-03","article-title":"Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor alpha and Akt inactivation","volume":"10","author":"Matei","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2005.09.041_bib8","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/cncr.11561","article-title":"Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium","volume":"98","author":"Schmandt","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2005.09.041_bib9","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1006\/gyno.1998.5121","article-title":"The effects of platelet-derived growth factor and receptor on normal and neoplastic human ovarian surface epithelium","volume":"71","author":"Dabrow","year":"1998","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2005.09.041_bib10","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/(SICI)1096-9896(199711)183:3<325::AID-PATH941>3.0.CO;2-A","article-title":"Abl expression in human fetal and adult tissues, tumours, and tumour microvessels","volume":"183","author":"O'Neill","year":"1997","journal-title":"J. Pathol."},{"key":"10.1016\/j.ygyno.2005.09.041_bib11","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1095\/biolreprod62.6.1600","article-title":"Expression and action of kit ligand\/stem cell factor in normal human and bovine ovarian surface epithelium and ovarian cancer","volume":"62","author":"Parrott","year":"2000","journal-title":"Biol. Reprod."},{"key":"10.1016\/j.ygyno.2005.09.041_bib12","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/1097-0215(20000520)89:3<242::AID-IJC6>3.0.CO;2-6","article-title":"Lack of expression of c-KIT in ovarian cancers is associated with poor prognosis","volume":"89","author":"Tonary","year":"2000","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ygyno.2005.09.041_bib13","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/0165-4608(94)90183-X","article-title":"Human ovarian tumors of epithelial origin express PDGF in vitro and in vivo","volume":"73","author":"Versnel","year":"1994","journal-title":"Cancer Genet. Cytogenet."},{"key":"10.1016\/j.ygyno.2005.09.041_bib14","first-page":"3049","article-title":"Coexpression of the c-kit receptor and the stem cell factor in gynecological tumors","volume":"54","author":"Inoue","year":"1994","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2005.09.041_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control. Clin. Trials"},{"key":"10.1016\/j.ygyno.2005.09.041_bib16","doi-asserted-by":"crossref","first-page":"9651","DOI":"10.1200\/jco.2004.22.14_suppl.9651","article-title":"A phase II clinical trial with proteomic profiling of imatinib mesylate in patients with refractory or relapsed epithelial ovarian cancer (EOC)","volume":"22","author":"Posadas","year":"2004","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2005.09.041_bib17","first-page":"5880","article-title":"Phase II study of imatinib in patients with small cell lung cancer","volume":"9","author":"Johnson","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2005.09.041_bib18","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/pros.20130","article-title":"A phase II trial of imatinib mesylate in patients with prostate specific antigen progression after local therapy for prostate cancer","volume":"62","author":"Rao","year":"2005","journal-title":"Prostate"},{"key":"10.1016\/j.ygyno.2005.09.041_bib19","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1200\/JCO.2005.06.125","article-title":"Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study","volume":"23","author":"Hotte","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2005.09.041_bib20","first-page":"956","article-title":"KIT protein expression and analysis of c-kit gene mutation in adenoid cystic carcinoma","volume":"12","author":"Holst","year":"1999","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.ygyno.2005.09.041_bib21","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1172\/JCI200317929","article-title":"Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors","volume":"111","author":"Bergers","year":"2003","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ygyno.2005.09.041_bib22","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1200\/JCO.2005.01.032","article-title":"Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume","volume":"23","author":"Jayson","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2005.09.041_bib23","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.ejca.2003.11.025","article-title":"Use of c-KIT\/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group","volume":"40","author":"Debiec-Rychter","year":"2004","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2005.09.041_bib24","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N. Engl. J. Med."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825805008395?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825805008395?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,7]],"date-time":"2019-02-07T18:04:34Z","timestamp":1549562674000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825805008395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,4]]}},"alternative-id":["S0090825805008395"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2005.09.041","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2006,4]]}}}